Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy
- 28 February 2010
- journal article
- research article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 73 (2), 156-166
- https://doi.org/10.1016/j.critrevonc.2009.02.001
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Menopausal symptoms and adjuvant therapy-associated adverse eventsEndocrine-Related Cancer, 2008
- Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialAnnals of Oncology, 2007
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast CancerNew England Journal of Medicine, 2005
- Patients' Understanding of and Compliance With Medications: The Sixth Vital Sign?Mayo Clinic Proceedings, 2005
- Adherence to MedicationNew England Journal of Medicine, 2005
- Medication adherence and persistence: A comprehensive reviewAdvances in Therapy, 2005
- The Importance of Medication Adherence in Improving Chronic-Disease Related OutcomesMedical Care, 2005
- Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancerThe Lancet, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- Annual hazard rates of recurrence for breast cancer after primary therapy.Journal of Clinical Oncology, 1996